Question Bank › From candidate to default

From candidate to default

From candidate to default: the company has just been placed inside buyers' own purchasing systems

Calls Tested
498
Answered YES
12
Hit Rate
2.4%
rare by design

CVS Health Corporation (CVS) — this company's answers

NO on the Q1 2018 call 2018-05-02 B+
The model's full reasoning — Q1 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权的选择”,从而进入买方的采购、报销、处方集、规格、采购、网络、目录或计划系统,使未来业务无需每次单独销售即可获得,并且管理层表示这种准入状态是新的,大部分量尚未反映在报告结果中。 在记录中,管理层讨论了与Aetna的合并、PBM业务、零售业务等。关于准入状态,有提到“preferred pharmacy in various Medicare Part D networks”(在多个Medicare Part D网络中的首选药房),以及“partnerships with PBMs and health plans across the industry”(与行业内的PBM和健康计划的合作)。但这是否是“最近”的转变?管理层提到“our expanded participation as a preferred pharmacy in various Medicare Part D networks”(我们在多个Medicare Part D网络中扩大参与作为首选药房),这暗示了最近的变化。此外,Dave Denton提到“we are seeing a greater benefit from the broader relationships we established last year with payers as well as from our expanded participation as a preferred pharmacy in various Medicare Part D networks.”(我们看到了去年与支付方建立的更广泛关系以及我们在多个Medicare Part D网络中扩大参与作为首选药房带来的更大好处。)这表明这些关系是最近建立的,并且正在带来好处。 然而,管理层是否明确表示这种准入状态是新的,并且大部分量尚未反映在结果中?Dave Denton说:“We are seeing a greater benefit from the broader relationships we established last year with payers as well as from our expanded participation as a preferred pharmacy in various Medicare Part D networks.”(我们看到了去年与支付方建立的更广泛关系以及我们在多个Medicare Part D网络中扩大参与作为首选药房带来的更大好处。)这暗示了这些关系是最近建立的,并且正在带来好处,但并未明确说“大部分量尚未反映”。此外,在讨论2019年销售季时,Jon Roberts提到“we are more than halfway through our 2019 renewals”(我们已过半2019年续约),但这是关于续约,不是新的准入。 关于“preferred pharmacy”地位,这确实是一种准入状态,但管理层是否说这是“最近”的?他们提到“expanded participation”,表明是扩大,但可能不是全新的。另外,在零售业务中,他们提到“partnerships with PBMs and health plans across the industry”,但这是普通合作关系。 关键点:管理层是否描述了公司从“候选”变为“默认”的转变?他们提到了“preferred pharmacy”地位,这确实是一种准入,但并未明确说这是新的,并且大部分量尚未反映。他们提到“we are seeing a greater benefit”,表明已经开始受益,但未说“大部分量尚未反映”。 此外,关于Aetna交易,那是待定的,不是已完成的准入。 因此,我认为没有明确描述这一现象。答案应为NO。

← Back to the full CVS analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of the company's future business can now arrive WITHOUT a discrete selling event for each order — AND does management convey that this access status is new enough that most of the volume it will unlock is still ahead of the reported results? Answer YES when management's own words convey this ONE phenomenon, in whatever form fits the industry: the company has moved from candidate toward default inside the routine pathway through which purchases get made. Example forms, all treated equally: being named to an approved or preferred supplier list, procurement schedule, purchasing program, or payer network; being written into specifications, standards, reference designs, configurations, protocols, or bundled defaults; being added to a formulary, reimbursement catalog, coding/payment pathway, formulary-like listing, or provider directory; being qualified onto a customer's, agency's, platform's, or program's roster; or comparable status that inserts the company into the system through which transactions routinely flow. The essential point is the EXCHANGE OF FRICTION STATUS: buying no longer has to be re-argued each time, because the company is now inside the pathway. For YES, management must also convey, directly or plainly in substance, that the status is recent and the flow through it is only beginning — so the results just reported capture little of what this access will bring. One such gateway, or several together, both qualify. Answer NO if the only access described is ordinary selling relationships, routine reseller/distribution agreements, or standard customer wins where each order still must be individually persuaded. NO if the relevant status has existed for years and is simply the company's steady way of going to market, with nothing new about the access. NO if the status is only pending, applied for, hoped for, or contingent on approvals not yet obtained. NO if management merely asserts that the product is "mission-critical," "a standard," or "the default choice" without describing a concrete buyer-side system the company has been placed into. NO if the business flowing through that status is already mature and substantially reflected in current results. NO if the access status or its significance appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
INGN Inogen, Inc. Q1 2023 2023-05-05 F
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
MGNI Magnite, Inc. Q1 2022 2022-05-04 D
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.

More from the question bank

Paying a named price today to serve businessEarnings outrunning the activityAnalysts converge on an emerging driverWorking harder than they are being paid forNumbers reset the ceilingDeliberately different by designAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.